Get the Stockscreener App
1.68
8.39%
0.13
Humacyte Inc stock is traded at $1.68, with a volume of 3.08M.
It is up +8.39% in the last 24 hours and down -44.19% over the past month.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.
See More
Previous Close:
$1.55
Open:
$1.55
24h Volume:
3.08M
Relative Volume:
0.92
Market Cap:
$231.13M
Revenue:
-
Net Income/Loss:
$-110.78M
P/E Ratio:
-1.5701
EPS:
-1.07
Net Cash Flow:
$-75.59M
1W Performance:
+7.01%
1M Performance:
-44.19%
6M Performance:
-65.43%
1Y Performance:
-46.15%
1-Day Range:
$1.55
$1.70
1-Week Range:
$1.43
$1.70
52-Week Range:
$1.15
$9.97
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
1.68 | 231.13M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Press Release Distribution & PR Platform - ACCESS Newswire
Humacyte responds to recent attacks By Investing.com - Investing.com Canada
Humacyte Challenges FDA Petition Amidst Controversy - TipRanks
Humacyte responds to recent attacks - Investing.com
Humacyte’s Promising Market Penetration and Revenue Projections Justify Buy Rating - TipRanks
Humacyte chief commercial officer purchases $9,999 in common stock - Investing.com Australia
Humacyte, Inc. (HUMA) Increases Despite Market Slip: Here's What You Need to Know - MSN
Humacyte chief commercial officer purchases $9,999 in common stock By Investing.com - Investing.com India
Humacyte CFO Dale Sander buys $30,600 in company stock - Investing.com Australia
Humacyte CFO Dale Sander buys $30,600 in company stock By Investing.com - Investing.com South Africa
Humacyte’s chief medical officer acquires $11,625 in common stock By Investing.com - Investing.com South Africa
Humacyte’s chief medical officer acquires $11,625 in common stock - Investing.com Australia
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Shareholders - ACCESS Newswire
Small-Caps Explode Higher As Tariff Fears Ease: Humacyte, Forward Air, FormFactor Top Russell 2000 - Benzinga
Investigation announced for Investors who hold shares of Humacyte, Inc. (NASDAQ: HUMA) - openPR.com
Humacyte director Charles Green acquires $7,740 in stock - Investing.com Australia
Humacyte director Michael Constantino buys $20,160 in stock By Investing.com - Investing.com South Africa
Humacyte director Kathleen Sebelius acquires $66,000 in common stock By Investing.com - Investing.com South Africa
Humacyte director Michael Constantino buys $20,160 in stock - Investing.com
Humacyte director Charles Green acquires $7,740 in stock By Investing.com - Investing.com India
Humacyte director Kathleen Sebelius acquires $66,000 in common stock - Investing.com
Humacyte Executives Increase Holdings with Recent Purchases - TradingView
Humacyte, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your RightsHUMA - ACCESS Newswire
Humacyte, Inc. (HUMA) Stock Moves -0.68%: What You Should Know - MSN
Humacyte’s $50 Million Common Stock Offering - Global Legal Chronicle
HUMA stock touches 52-week low at $1.3 amid market challenges By Investing.com - Investing.com South Africa
Investors who lost money on Humacyte, Inc.(HUMA) should contact Levi & Korsinsky about pending Class ActionHUMA - ACCESS Newswire
Shareholders that Lost Money on Humacyte, Inc. (HUMA) Should Contact Levi & Korsinsky about Pending Class ActionHUMA - ACCESS Newswire
Shareholders of Humacyte, Inc. Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your RightsHUMA - ACCESS Newswire
Humacyte, Inc. (NASDAQ:HUMA) Q4 2024 Earnings Call Transcript - Insider Monkey
Humacyte’s Earnings Call: Balancing Achievements and Challenges - TipRanks
Humacyte Stock (HUMA) Hits Record Low Post Q4 Results Despite FDA Nod for Vascular Trauma Treatment - markets.businessinsider.com
symbol__ Stock Quote Price and Forecast - CNN
Benchmark maintains Buy rating, $17 target on Humacyte stock By Investing.com - Investing.com UK
Humacyte, Inc. Class Action: Levi & Korsinsky Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025HUMA - ACCESS Newswire
Humacyte Inc. Warrant (HUMAW) reports earnings - qz.com
Humacyte down following quarterly results, hits record low - MSN
Shareholders that lost money on Humacyte, Inc.(HUMA) should contact Levi & Korsinsky about pending Class ActionHUMA - ACCESS Newswire
Humacyte Stock Continues Slide Despite Lower Than Expected Q4 Loss – But Retail Gets More Bullish - MSN
Humacyte price target lowered to $8 from $10 at BTIG - Yahoo Finance
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):